HBV合并HEV感染导致慢加急性肝衰竭HBV-PC区变异及临床特征分析

摘要/Abstract

摘要： 目的分析乙型肝炎病毒合并戊型肝炎病毒导致的慢加急性肝衰竭的HBV-PC区变异及临床特征。方法回顾性分析HBV感染的慢加急性肝衰竭(ACLF)患者69例,其中单独HBV感染患者39例,HBV合并HEV感染患者30例;比较2组患者肝功能、HBV DNA水平、凝血功能、MELD评分以及预后情况;PCR扩增HBV-PC区序列,测序与ACLF相关的变异位点A1762T、G1764A、C1766T、T1768A、G1896A、A1762T+G1764A、G1764A+C1766T+T1768A,比较两组患者之间的差异。分析HBV合并HEV感染存活与死亡患者,Logistic回归分析重叠感染患者预后相关因素。结果与单纯 HBV感染组比较,合并HEV感染组患者的TBil[(216.4 ± 12.1) μmol/L对(364.2 ± 170.24) μmol/L]、肝性脑病发生率(17.9%对33.3%)、MELD评分(21.26 ± 6.65对28.26 ± 8.65 )均呈不同程度的升高;PTA [(33.3±22.4)%对(24.5±20.1)%]明显降低,差异均有统计学意义(P<0.05);2组患者HBV-PC变异分析比较位点A1762T(66.7%对76.7%)、G1764A(69.2%对80.0%)、A1762T+G1764A(59.0%对70.0%)和G1764A+C1766T+T1768A(2.6%对10.0%) 差异有统计学意义(P<0.05)。HBV合并HEV感染患者存活组与死亡组比较,MELD评分和肝性脑病发生率明显升高,PTA明显降低,差异均有统计学意义(P<0.05); HBV-PC变异分析比较G1764A+C1766T+T1768A 三联变异差异有统计学意义(P<0.05);Logistic回归分析显示,TBil(P=0.006,OR=2.672)、PTA(P=0.036,OR=2.115)、MELD评分(P=0.003,OR=1.682)、肝性脑病并发症(P=0.001,OR=3.631)和G1764A+C1766T+T1768A 三联变异(P=0.043,OR=2.081)因素与预后有关。结论单独HBV与合并HEB感染导致的ACLF患者病情更加严重,预后更差。TBil、MELD评分、肝性脑病并发症和HBV-PC区G1764A+C1766T+T1768A 三联变异发生率越高。PTA越低,ACLF患者预后越差。

关键词: 乙型肝炎病毒, 戊型肝炎病毒, 慢加急性肝衰竭, HBV-PC区变异

Abstract: Objective To study hepatitis B virus (HBV) basic core promoter and pre-C (PC) nucleotides mutations in patients coinfected with hepatitis E virus (HEV) related acute on chronic liver failure (ACLF) , and to analyze the clinical characteristics.Methods Sixty-nine cases with ACLF caused by HBV infection were retrospectively analyzed, of which 39 patients suffered single HBV infection, and the other 30 patients suffered HBV and HEV coinfection. Liver function, HBV DNA level, blood coagulation function, model for end stage liver disease (MELD) score and prognosis of the two groups were compared respectively. Polymerase chain reaction (PCR) was used for assessing HBV PC region amplification. Sequencing analysis was applied to detect reported ACLF-related mutation sites A1762T, G1764A, C1766T, T1768A, G1896A, A1762T + G1764A and G1764A + C1766T + T1768A for comparative analysis between the two groups. The survival rates and mortality of patients with HBV and HEV coinfection were evaluated for related prognostic factors by logistic regression analysis. Results In the coinfection group, total bilirubin (TBiL), incidence of hepatic encephalopathy and levels of the MELD score were significantly increased (216.4 ± 12.1 vs 364.2 ± 170.24, 17.9% vs 33.3%, 21.26 ± 6.65 vs 28.26 ± 8.65, respectively) when compared with those in single infection group, while prothrombin time activity (PTA) was obviously decreased (33.3 ± 22.4 vs 24.5 ± 20.1) (P<0.05). The comparative analysis of HBV-PC mutation sites A1762T (66.7% vs 76.7%), G1764A (69.2% vs 80.0%), A1762T+G1764A (59.0% vs 70.0%) and G1764A+C1766T+T1768A (2.6% vs 10.0%) showed statistically differences between the two groups (P<0.05). Additionally, among HBV and HEV coinfection patients, the MELD score and incidence of hepatic encephalopathy in death group increased significantly when compared to those in survival group, but the PTA decreased obviously (P<0.05). The comparative analysis of HBV-PC mutation site G1764A + C1766T + T1768A triplet mutation also showed significant difference (P<0.05) between the two groups in patients with coinfection. The logistic regression analysis suggested that TBiL (P=0.006, OR=2.672), PTA (P=0.036, OR=2.115), MELD score (P=0.003, OR=1.682), hepatic encephalopathy incidence (P=0.001, OR=3.631) and G1764A + C1766T + T1768A triplet mutation (P=0.043, OR=0.043) were all related to the prognosis.Conclusion The prognosis is poor in ACLF patients caused by HBV and HEV coinfection, which could be indicated from high TBiL level, MELD score, incidence of hepatic encephalopathy and HBV-PC area G1764A+C1766T+T1768A triplet mutation rate. Furthermore, lower PTA level always predicts a worse prognosis.

Key words: Hepatitis B virus, Hepatitis E virus, Acute-on-chronic liver failure, HBV-PC nucleotides mutations

信亮亮, 李冰, 荣义辉. HBV合并HEV感染导致慢加急性肝衰竭HBV-PC区变异及临床特征分析[J]. 肝脏, 2016, 21(3): 168-171.

XIN Liang-liang, LI Bing, RONG Yi-hui. Analysis of HBV PC mutations in ACLF patients infected with HBV combined HEV and their clinical characteristics[J]. Chinese Hepatolgy, 2016, 21(3): 168-171.

参考文献

1 Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology, 2006,44:326-334.
2 Chen MT, Billaud JN, Sallberg M, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.Proc Natl Acad Sci USA, 2004, 101: 14913.
3 中国医师协会感染科医师分会. 戊型病毒性肝炎诊疗规范. 中华临床感染病杂志, 2009, 2: 260-263.
4 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝炎与人工肝学组. 肝衰竭诊治指南(2012年版). 中华临床感染病杂志,2012, 5(6): 321-327.
5 Xu ZH, Ren XQ, Liu Y, et al. Association of hepatitis B virus mutations in basal core promoterand precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol, 2011, 46: 391-400.
6 WHO. Viral hepatitis in the WHO south-east Asia region. India: regional office for south-east Asia, 2011.
7 Acharya SK, Sharma PK, Singh RA, et al. Hepatitis E virus(HEV) infection in patients with cirrhosis associated with rapid decompen sation and death.J Hepatol, 2007, 46: 387-394.
8 Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology,2012,142:1388.
9 Salam GD, Kumar A, Kar PA, et al. Serum tumor necrosis factor-alpha level in hepatitis E virus-related acute viral hepatitis and fulminant hepatic failure in pregnant women.Hepatol Res, 2013,43:826-835.
10 Gérolami R, Henry M, Borentain P, et al. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis, 2005, 40: 24.
11 Sun QF, Ding JG, Xu DZ, et al. Prediction of theprognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat,2009,16: 464-470.
12 丁剑波,罗晓岚,田一梅,等. 慢性乙型重型肝炎预后影响因素 Logistic回归分析.传染病信息,2012,25:161-163.
13 王耀,刘妍,许智慧,等.G1764A/C1766T/T1768A三联突变对HBV核心启动子活性的上调作用.解放军医学杂志,2010,35: 954-957.

[1]	王建文, 刘大东, 马鸿杰. 慢加急性肝衰竭合并侵袭性真菌感染患者的临床特征和预后影响因素分析[J]. 肝脏, 2020, 25(5): 507-509.
[2]	周培, 渠淑云. 替诺福韦阻断高HBV DNA载量孕妇母婴传播临床效果观察[J]. 肝脏, 2020, 25(4): 393-395.
[3]	李永涛, 卜贤玉, 李滨. 替诺福韦酯补救治疗对HBV感染肝硬化患者的疗效分析[J]. 肝脏, 2020, 25(4): 400-402.
[4]	黄珊珊, 赵静雅, 陈洁, 杨扬. 前列腺素E2促进乙型肝炎病毒复制的机制研究[J]. 肝脏, 2020, 25(3): 277-281.
[5]	王贤, 林涛发, 詹志瑜, 王少扬. 不同免疫状态慢性HBV感染患者的T淋巴细胞及NKG2D表达差异研究[J]. 肝脏, 2020, 25(2): 131-134.
[6]	龙云铸, 贺萧瑾, 李丹, 周娟, 周青, 谭英征. HBx介导SOCS-1基因甲基化致肝细胞癌发生的机制[J]. 肝脏, 2020, 25(2): 202-205.
[7]	袁宏香, 张秋云, 娄金丽, 于艳华, 赵艳. 慢加急性肝衰竭血小板减少患者血栓弹力图及常规凝血指标的变化[J]. 肝脏, 2020, 25(1): 20-23.
[8]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.
[9]	王欣茹, 肖丽, 杨莉莉, 张会, 汤小霞, 孙鸿展, 咸建春. 不同年龄孕妇HBV感染现状的血清流行病学分析[J]. 肝脏, 2020, 25(1): 76-77.
[10]	张志侨, 叶一农, 何纲, 王鹏, 李静, 吴兴柳. 乙型肝炎相关慢加急性肝衰竭患者急性肾损伤的影响因素和高危人群分析[J]. 肝脏, 2019, 24(9): 997-1001.
[11]	刘亚迪, 孙双双, 徐浩, 李成忠. HBV相关慢加急性肝衰竭患者感染特点及危险因素分析[J]. 肝脏, 2019, 24(9): 1015-1019.
[12]	诸海军, 万健, 孙莲娜, 孙杰, 陈嵩. WBC、IL-6及NLR值对慢加急性肝衰竭患者的早期预警价值[J]. 肝脏, 2019, 24(9): 1076-1078.
[13]	钟慧筠, 殷思纯. HBV相关慢加急性肝衰竭器官衰竭危险因素及短期预后分析[J]. 肝脏, 2019, 24(6): 658-661.
[14]	华燕美. 两种乙型肝炎病毒核酸定量检测试剂的检验重复性与一致性比较[J]. 肝脏, 2019, 24(6): 692-694.
[15]	苏金良, 陈慧, 朱莉, 陆敏嘉, 李明. HBV相关慢加急性肝衰竭前期外周血中Toll样受体3、4的表达[J]. 肝脏, 2019, 24(5): 499-502.